Drug Profile
Ranibizumab biosimilar - Formycon
Alternative Names: CHS 201; CIMERLI; FYB 201; LUCENTIS; Ongavia; Ranibizumab biosimilar - Formycon/Bioeq/Coherus BioSciences; ranibizumab-eqrn; Ranivisio; RanoptoLatest Information Update: 29 Jan 2024
Price :
$50
*
At a glance
- Originator Formycon
- Developer Bioeq; Formycon; Teva Pharmaceutical Industries
- Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Wet age-related macular degeneration
Highest Development Phases
- Marketed Choroidal neovascularisation; Diabetic macular oedema; Diabetic retinopathy; Retinal oedema; Wet age-related macular degeneration